Flavia L.
- Country
- Italy
- Department
- Divisione di Ematologia
Research Overview
- Phase II Study of Daratumumab with Bortezomib-Cyclophosphamide-Dexamethasone vs. Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Multiple Myeloma Patients
- Phase III Randomized Trial of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Ineligible for ASCT
- Evaluation of Isatuximab and Dexamethasone in Autologous Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma Patients
Data & Insights
Has run more than one trial at 24 of 62 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating multiple myeloma, with particular focus on both newly diagnosed cases and relapsed disease states. Their expertise extends to managing patients through various stages of the disease progression.
- Newly Diagnosed Multiple Myeloma
- Relapsed Multiple Myeloma
- Autologous Stem Cell Transplantation
Treatment Approaches
The investigator works with novel therapeutic combinations including immunomodulatory agents and proteasome inhibitors. Their clinical focus encompasses both transplant-eligible and relapsed patient populations.
- Combination Therapy Strategies
- Salvage Therapy
- Maintenance Therapy
Treatment Optimization
Their work involves evaluating therapeutic responses in hematologic malignancies, with particular attention to treatment efficacy and patient outcomes in various disease stages.
- Response Assessment
- Disease Progression Monitoring
- Long-term Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.